Tacrolimus

Generic Name
Tacrolimus
Brand Names
Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
Drug Type
Small Molecule
Chemical Formula
C44H69NO12
CAS Number
104987-11-3
Unique Ingredient Identifier
Y5L2157C4J
Background

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...

Indication

Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...

Associated Conditions
Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
Associated Therapies
-
Clinical Trials
Related News

Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy

First Posted Date
2022-02-03
Last Posted Date
2022-02-03
Lead Sponsor
Leiden University Medical Center
Target Recruit Count
86
Registration Number
NCT05221411
Locations
🇳🇱

Medisch Spectrum Twente, Enschede, Netherlands

🇳🇱

Leiden University Medical Center, Leiden, Netherlands

🇳🇱

Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands

and more 3 locations

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

First Posted Date
2022-01-21
Last Posted Date
2023-04-04
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
61
Registration Number
NCT05202145
Locations
🇺🇸

Clinical Study Site, Tempe, Arizona, United States

BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

First Posted Date
2021-12-14
Last Posted Date
2024-12-12
Lead Sponsor
Sanofi
Target Recruit Count
45
Registration Number
NCT05156710
Locations
🇺🇸

Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007, Boston, Massachusetts, United States

🇺🇸

Cedars-Sinai Medical Center- Site Number : 8400100, Los Angeles, California, United States

🇺🇸

University of California Los Angeles Medical Center- Site Number : 8400103, Los Angeles, California, United States

and more 25 locations

Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)

First Posted Date
2021-12-08
Last Posted Date
2024-03-15
Lead Sponsor
Université de Sherbrooke
Target Recruit Count
414
Registration Number
NCT05148715
Locations
🇨🇦

L'Institut de Cardiologie de Montréal, Montréal, Quebec, Canada

🇨🇦

Centre Hospitalier Universitaire de Montréal, Montréal, Quebec, Canada

🇨🇦

Centre universitaire de santé McGill (CUSM), Montréal, Quebec, Canada

and more 4 locations

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

First Posted Date
2021-11-10
Last Posted Date
2024-12-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
24
Registration Number
NCT05115630
Locations
🇺🇸

M D Anderson Caner Center, Houston, Texas, United States

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

First Posted Date
2021-11-05
Last Posted Date
2021-11-05
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
72
Registration Number
NCT05109390
Locations
🇺🇸

Clinical Trial Site, Tempe, Arizona, United States

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

First Posted Date
2021-10-21
Last Posted Date
2024-02-20
Lead Sponsor
Stanford University
Target Recruit Count
40
Registration Number
NCT05088356
Locations
🇺🇸

Stanford University, Stanford, California, United States

NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation

First Posted Date
2021-10-12
Last Posted Date
2023-05-11
Lead Sponsor
University College, London
Registration Number
NCT05073822

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

First Posted Date
2021-09-02
Last Posted Date
2024-10-14
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
63
Registration Number
NCT05031897
Locations
🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

First Posted Date
2021-08-31
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
54
Registration Number
NCT05027945
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy